Literature DB >> 24771135

CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.

Nadine Hömberg1, Christian Adam, Tanja Riedel, Christoph Brenner, Andrew Flatley, Martin Röcken, Ralph Mocikat.   

Abstract

It is well established that an interplay between natural killer (NK) cells and dendritic cells (DCs) gives rise to their reciprocal activation and provides a Th1-biased cytokine milieu that fosters antitumor T-cell responses. Ex vivo-differentiated DCs transferred into mice strongly stimulate endogenous NK cells to produce interferon (IFN)-γ and initiate a cascade that eventually leads to cytotoxic T-lymphocyte responses. We show that the ability of exogenous DCs to trigger this pathway obviates CD40 signaling and CD4(+) T-cell help and depends on a preceding maturation step. Importantly, this mechanism was also effective in endogenously arising tumors where IFN-γ production is compromised in contrast to transplantable tumors. In c-myc-transgenic mice developing spontaneous lymphomas, injection of unpulsed DCs caused NK-cell activation and induced CD8(+) T cells capable of recognizing the lymphoma cells. Animals treated with unpulsed DCs showed a survival benefit compared to untreated myc mice. Hence, tumor immunity induced by DC-based vaccines not only depends on specific antigens loaded on the DCs. Rather, DC vaccines generate broader immune responses, because endogenous DCs presenting tumor antigens may also become stimulated by NK cells that were activated by exogenous DCs. Thus, the DC/NK-cell/cytotoxic T lymphocyte axis may commonly have relevance for DC-based vaccination protocols in clinical settings.
© 2014 UICC.

Entities:  

Keywords:  CTL response; DC maturation; adaptive antitumor immunity; interferon-γ; λ-myc mouse

Mesh:

Substances:

Year:  2014        PMID: 24771135     DOI: 10.1002/ijc.28932

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Chronic Myelocytic Leukemia (CML) Patient-Derived Dendritic Cells Transfected with Autologous Total RNA Induces CML-Specific Cytotoxicity.

Authors:  Li Yu; Ting Hu; Tian Zou; Qingzhi Shi; Guoan Chen
Journal:  Indian J Hematol Blood Transfus       Date:  2016-01-21       Impact factor: 0.900

2.  Therapeutic vaccines for aggressive B-cell lymphoma.

Authors:  Zijun Y Xu-Monette; Ken H Young
Journal:  Leuk Lymphoma       Date:  2020-08-25

3.  Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner.

Authors:  Sébastien Anguille; Heleen H Van Acker; Johan Van den Bergh; Yannick Willemen; Herman Goossens; Viggo F Van Tendeloo; Evelien L Smits; Zwi N Berneman; Eva Lion
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

4.  Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours.

Authors:  Ellen Brenner; Barbara F Schörg; Fatima Ahmetlić; Thomas Wieder; Franz Joachim Hilke; Nadine Simon; Christopher Schroeder; German Demidov; Tanja Riedel; Birgit Fehrenbacher; Martin Schaller; Andrea Forschner; Thomas Eigentler; Heike Niessner; Tobias Sinnberg; Katharina S Böhm; Nadine Hömberg; Heidi Braumüller; Daniel Dauch; Stefan Zwirner; Lars Zender; Dominik Sonanini; Albert Geishauser; Jürgen Bauer; Martin Eichner; Katja J Jarick; Andreas Beilhack; Saskia Biskup; Dennis Döcker; Dirk Schadendorf; Leticia Quintanilla-Martinez; Bernd J Pichler; Manfred Kneilling; Ralph Mocikat; Martin Röcken
Journal:  Nat Commun       Date:  2020-03-12       Impact factor: 14.919

5.  Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence.

Authors:  Martin Röcken; Ralph Mocikat; Fatima Ahmetlic; Josia Fauser; Tanja Riedel; Vera Bauer; Carolin Flessner; Nadine Hömberg; Roman Hennel; Ellen Brenner; Kirsten Lauber
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

6.  Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Authors:  Guoqi Song; Huiyun Ni; Linqing Zou; Shukui Wang; Fuliang Tian; Hong Liu; William C Cho
Journal:  Onco Targets Ther       Date:  2016-06-23       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.